The Pepwizard Q2 2026 Peptide Index

Executive summary

Three forces defined peptide demand in Q1 2026:

1. GHK-Cu broke out of the research niche. Topical copper peptides accounted for 220K US monthly searches — up 1,016% year-on-year and surpassing every GLP-class peptide except tirzepatide and semaglutide.
2. Retatrutide pulled forward the GLP efficacy frontier. Lilly's triple agonist produced 28.7% body-weight reduction in Phase 3 at 48 weeks, and search demand rose 512% YoY ahead of approval.
3. RFK Jr / HHS returned 14 peptides to legal compounding. Including BPC-157, TB-500, and most GH secretagogues. The US gray market ($328M in 2025 imports) is re-integrating with licensed channels rather than shrinking.

Catalogue growth

Pepwizard now tracks 32 vendors offering 104 live offers across 29 peptides and 8 form factors. Every offer is normalised to £/mg at the current FX rate. Core catalogue additions this quarter: orforglipron (first oral GLP-1), cagrilintide (amylin agonist for CagriSema), and Russian bioregulator cluster (Vladonix, Endoluten, Pinealon, DSIP).

Price trends

• Tirzepatide median £/mg fell 14% as Apollo, Core and Pinnacle competed into the research-chemical channel.
• BPC-157 held around £6.9/mg at the cheapest UK-domestic vendor (Peptides UK) despite WADA adding it to the prohibited list in early 2025.
• GHK-Cu topical category prices compressed as The Ordinary and HydroPeptide ran spring promotions — median dropped from £38 to £27 across the tracked set.
• Retatrutide street-price floor is £22/mg via Pinnacle. Every vendor adding it this quarter undercut the one before.

Regulation

Five material events since January:

• Feb 2026 — HHS reclassification restored compounding status for ~14 peptides (BPC-157, TB-500, sermorelin, and GH secretagogues confirmed).
• Mar 2026 — Peptide Sciences EU shutdown created a supply gap filled by Slovak and Cypriot replacements.
• Jan 2026 — Eli Lilly filed orforglipron NDA with the FDA.
• Projected: FDA scheduled to vote on BPC-157 status in mid-July 2026.
• Outside the US: UK MHRA expanded Mounjaro access in December 2025; EU regulators continued tightening on unapproved peptide marketing.

Vendor landscape

The 32-vendor field is becoming stratified by commercial tier:

• Tier 1 (research peptides): 25 vendors. Commission range 5–20%. Apollo Peptide Sciences leads on economics: 20% base + lifetime rebill, 120-day cookie.
• Tier 2 (telehealth / GLP-1): 3 vendors. Flat CPA $20–60. Paid-ad safe.
• Tier 3 (cosmetic & supplement): 4 vendors. Lower margins (5–12%) but paid-social eligible and best aligned for the GHK-Cu topical surge.

Narrative drivers

Four social forces kept search demand rising:

• Joe Rogan credited peptides for injury recovery on multiple 2025 episodes; each spike added measurable search demand.
• RFK Jr's HHS announcement became one of the most-watched medical-policy videos of Q1 2026.
• Gray-market imports from China hit $328M in 2025, per industry trade press.
• Beauty-industry adoption of "peptide therapy" terminology pulled cosmetic buyers into the category — TikTok search for "peptide therapy" up 459% YoY.

Methodology

Pricing: 104 vendor offers scraped daily, stored with lastChecked timestamp, normalised to £/mg using current GBP FX rates (USD 0.79, EUR 0.87). Out-of-stock offers are retained but excluded from "best price" calculations.

Search volume: Google Trends via public exports, rounded to the nearest 5K. TikTok and Instagram growth from Spate market research (via Glossy).

Regulatory: public statements from HHS, FDA, MHRA, EMA, WADA. Linked to primary sources on the Pepwizard regulation tracker.

What to watch in Q3

• July 2026 FDA vote on BPC-157 — outcome will reset the US gray market.
• Orforglipron approval decision — reshapes the economics of the GLP-1 category.
• Q2 earnings season — Novo Nordisk vs Lilly revenue splits on GLP-1.
• Continued GHK-Cu topical normalisation — mainstream retail entrants expected.
• Cagrilintide standalone momentum — if CagriSema Phase 3 hits, expect a new competitive front for Novo.